Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22389473 | 0.83 | PARP10 (0.49) | PARP10PARP15FFAR4ACACA | |
| SCHEMBL22957701 | 0.82 | PARP10 (0.43) | PARP10PARP15FFAR4ACACAFFAR1 | |
| SCHEMBL30468346 | 0.80 | PARP10 (0.49) | PARP10PARP15FFAR4 | |
| SCHEMBL20208258 | 0.80 | PARP10 (0.49) | PARP10PARP15FFAR4 | |
| SCHEMBL23841515 | 0.80 | NQO1 (0.43) | FFAR4FFAR1 | |
| SCHEMBL22389468 | 0.79 | RIPK1 (0.52) | PARP10PARP15FFAR4FFAR1 | |
| SCHEMBL22957703 | 0.79 | NOS1 (0.47) | PARP10PARP15FFAR4 | |
| SCHEMBL23434787 | 0.79 | PTGS1 (0.44) | FFAR4ACACB | |
| SCHEMBL20374442 | 0.79 | PARP10 (0.45) | PARP10PARP15FFAR4ACACAFFAR1 | |
| SCHEMBL19242600 | 0.78 | PARP10 (0.42) | PARP10PARP15FFAR4ACACAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | PARP10 374/4885PARP15 267/4885FFAR4 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.